MLN4924 and Neddylation Pathway Inhibition: Expanding Strategies for mTORC1-Driven Tumorigenesis

Introduction

Neddylation, a ubiquitin-like post-translational modification, is a pivotal regulator of protein stability, activity, and localization, with profound implications for cell cycle regulation and cancer biology. Aberrant activation of the neddylation cascade, driven by dysregulation of NEDD8-activating enzyme (NAE) and downstream effectors, has been documented in diverse solid tumor models. The selective NAE inhibitor for cancer research, MLN4924, has emerged as a cornerstone compound for interrogating the mechanistic links between neddylation inhibition, cullin-RING ligase (CRL) ubiquitination, and tumor growth inhibition in xenograft models. While previous studies have centered on cullin modification and CRL-mediated substrate degradation, recent research uncovers a broader network of neddylation substrates, including small GTPases such as RHEB, which directly potentiate mTORC1 pathway activity and tumorigenesis (Zhang et al., 2025).

Neddylation Pathway: Enzymology and Oncogenic Implications

The neddylation process is catalyzed by a cascade of enzymes: NEDD8-activating enzyme E1 (NAE), NEDD8-conjugating E2 enzymes (NCEs; UBE2M and UBE2F), and substrate-specific NEDD8 E3 ligases. Canonically, UBE2M partners with RBX1 to promote neddylation of cullins 1–4, activating CRLs1–4, whereas UBE2F pairs with SAG/RBX2 to neddylate cullin-5 and drive CRL5 activation. CRLs, as the largest family of E3 ubiquitin ligases, orchestrate the ubiquitination and proteasomal degradation of numerous regulatory proteins, thereby maintaining cellular homeostasis and dictating proliferation, apoptosis, and DNA repair mechanisms.

Mounting evidence implicates over-activation of neddylation in hepatocellular carcinoma (HCC), lung, and colorectal cancers, with upregulated NAE activity and CRL hyperactivation contributing to tumor growth, treatment resistance, and metabolic dysregulation. Notably, neddylation inhibition has demonstrated efficacy in reversing fibrogenic progression and promoting apoptosis in hepatic stellate cells, while genetic ablation of neddylation pathway components yields context-dependent phenotypes, including hepatocyte death and inflammation (Zhang et al., 2025).

MLN4924: Mechanistic Profile and Selectivity

MLN4924 (SKU: B1036) is a potent and selective NAE inhibitor, displaying an IC₅₀ of 4 nM. It binds competitively to the nucleotide-binding site of NAE, obstructing the formation of the Ubc12–NEDD8 thioester intermediate and subsequent neddylation of cullin and non-cullin targets. This blockade leads to decreased assembly of NEDD8–cullin conjugates, thereby inhibiting CRL-mediated ubiquitination and the degradation of key regulatory proteins. For example, MLN4924-induced accumulation of CDT1 triggers cell cycle arrest and apoptosis, highlighting the therapeutic potential of neddylation pathway inhibition in cancer biology research.

MLN4924 demonstrates remarkable selectivity, with substantially higher IC₅₀ values for related enzymes—UAE, SAE, UBA6, and ATG7—minimizing off-target effects. In cellular assays (e.g., HCT-116 colon carcinoma cells), MLN4924 elicits dose-dependent NAE inhibition, while in vivo studies reveal significant tumor growth inhibition in xenograft models (HCT-116, H522, Calu-6) at 30–60 mg/kg dosing, with minimal systemic toxicity. The physicochemical profile of MLN4924 (molecular weight 443.53, high solubility in DMSO/ethanol, insolubility in water) aligns with its use in both in vitro and in vivo research applications, provided solutions are freshly prepared and stored at -20°C.

Expanding Substrate Scope: RHEB Neddylation and mTORC1 Activation

Traditionally, the biological effects of neddylation inhibitors like MLN4924 have been attributed primarily to cullin modification and associated changes in CRL activity. However, the recent study by Zhang et al. (2025) broadens this paradigm by identifying RHEB, a small GTPase and direct activator of mTORC1, as a non-cullin neddylation substrate. RHEB undergoes neddylation at lysine 169 via the UBE2F–SAG E2/E3 axis, which enhances its lysosomal localization and GTP-binding affinity, thereby potentiating mTORC1 signaling. This post-translational modification is critical for sustaining the anabolic and proliferative demands of cancer cells, particularly in HCC, where mTORC1 hyperactivity is frequently observed.

Functional studies revealed that UBE2F depletion abrogates RHEB neddylation, inactivates mTORC1, impairs cell cycle progression, and triggers autophagy in vitro. Liver-specific Ube2f knockout in mouse models attenuated steatosis and tumorigenesis induced by Pten loss, underscoring a causal role for the UBE2F–SAG–RHEB axis in hepatic tumorigenesis. Importantly, UBE2F expression and mTORC1 activity correlated with adverse clinical outcomes in HCC patients, positioning the neddylation pathway as a tractable target for anti-cancer therapeutic development.

Practical Guidance: Leveraging MLN4924 for Mechanistic and Translational Studies

Given these mechanistic advances, researchers can deploy MLN4924 not only to dissect cullin-dependent CRL regulation, but also to interrogate the broader landscape of neddylation substrates implicated in oncogenic signaling pathways. Experimental strategies may include:

• Cell Cycle and Proliferation Assays: MLN4924 treatment in cultured cancer cell lines enables quantification of cell cycle progression, apoptosis induction, and autophagic flux, providing insights into neddylation-dependent regulation of key substrates such as CDT1 and RHEB.
• mTORC1 Activity Readouts: Combined use of MLN4924 with phospho-specific immunoblotting for mTORC1 targets (e.g., S6K1, 4EBP1) facilitates the dissection of neddylation-mediated modulation of mTORC1 signaling.
• Xenograft and Solid Tumor Models: In vivo administration of MLN4924 at 30–60 mg/kg supports evaluation of tumor growth inhibition, toxicity, and mechanistic endpoints, as demonstrated in HCT-116 and lung carcinoma models.
• Proteomic Profiling: Application of MLN4924 in conjunction with mass spectrometry-based proteomics can reveal novel neddylation substrates and inform target validation for anti-cancer therapeutic development.

Importantly, the selectivity of MLN4924 for NAE over other ubiquitin-like activating enzymes ensures specificity in targeting the neddylation pathway, enhancing the interpretability of experimental outcomes.

Implications for Anti-Cancer Therapeutic Development

The convergence of neddylation pathway inhibition and mTORC1 signaling modulation offers a compelling avenue for anti-cancer therapeutic development. As delineated in the study by Zhang et al. (2025), selective targeting of the UBE2F–SAG–RHEB axis may attenuate tumorigenic signaling in HCC and other malignancies characterized by mTORC1 hyperactivity. MLN4924, as a tool compound, enables preclinical modeling of these interventions, supporting both mechanistic elucidation and translational research. Moreover, its application in combination regimens or in genetically engineered mouse models may further clarify context-dependent dependencies on neddylation in solid tumor models.

Researchers should consider the temporal dynamics and tissue-specific consequences of neddylation pathway inhibition, as chronic suppression may yield distinct phenotypes compared to acute pharmacological blockade. Integration of MLN4924-based studies with genetic and omics approaches will be critical for deconvoluting these effects and identifying patient populations most likely to benefit from neddylation-targeted therapies.

Conclusion: Distinct Perspectives and Future Directions

This article extends the current understanding of MLN4924 and neddylation pathway inhibition by integrating recent discoveries on non-cullin substrates such as RHEB and their role in mTORC1-driven tumorigenesis. Unlike previous reviews, such as MLN4924: Selective NAE Inhibitor Illuminates Neddylation ..., which focus primarily on cullin modification and CRL regulation, this piece emphasizes the mechanistic and translational significance of expanding the substrate scope of neddylation. By highlighting practical guidance for MLN4924 application and exploring the interplay between neddylation and mTORC1 signaling, this article provides a novel framework for leveraging selective NAE inhibition in cancer biology research and anti-cancer therapeutic development.